Alpha Tau Medical (NASDAQ: DRTS) shareholders back board, pay and auditor at AGM

Rhea-AI Filing Summary

Alpha Tau Medical Ltd. reported the results of its Annual General Meeting of Shareholders held on June 23, 2026 in Jerusalem. Shareholders re-elected David Milch and Ruth Alon as Class II directors, with terms running until the annual meeting expected in 2029.

They also re-approved the company’s Compensation Policy for Executive Officers and Directors, confirmed CEO Uzi Sofer to continue serving as both Chief Executive Officer and Chairman of the Board, approved his compensation package, and extended the terms of certain options for directors and officers.

In addition, shareholders re-appointed Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm for the year ending December 31, 2026, with the board authorized to set audit fees.

Key Figures

AGM date: June 23, 2026 Director term end: Annual meeting in 2029 Audit year: Year ending December 31, 2026 +1 more

4 metrics

AGM date June 23, 2026 Date of Annual General Meeting of Shareholders

Director term end Annual meeting in 2029 Term for re-elected Class II directors

Audit year Year ending December 31, 2026 Period for re-appointed independent auditor

Incorporated forms Form F-3 and Form S-8 This report incorporated into multiple registration statements

Key Terms

Annual General Meeting of Shareholders, Class II directors, Compensation Policy for Executive Officers and Directors, independent registered public accounting firm, +1 more

5 terms

Annual General Meeting of Shareholders financial

"held its Annual General Meeting of Shareholders (the “Meeting”) at the Company’s headquarters"

Class II directors financial

"To re-elect each of David Milch and Ruth Alon as Class II directors, to hold office"

Compensation Policy for Executive Officers and Directors financial

"To re-approve the Company’s Compensation Policy for Executive Officers and Directors"

independent registered public accounting firm financial

"as the Company’s independent registered public accounting firm for the year ending December 31, 2026"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Companies Law 5759-1999 regulatory

"in accordance with our Amended and Restated Articles of Association or the Companies Law 5759-1999"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/25/2026 - 04:01 PM Accepted by SEC EDGAR 06/25/2026 - 04:01 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-41316

Alpha Tau Medical Ltd.

(Exact Name of Registrant as Specified in Its Charter)

Kiryat HaMada St. 5 

Jerusalem, Israel 9777605 

+972 (3) 577-4115 

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

CONTENTS

On June 23, 2026, Alpha Tau Medical Ltd. (the “Company”) held its Annual General Meeting of Shareholders (the “Meeting”) at the Company’s headquarters at 5 Kiryat Hamada St., Jerusalem 9777605, Israel.

At the Meeting, the Company’s shareholders approved the following proposals:

	(1)	To re-elect each of David Milch and Ruth Alon as Class II directors, to hold office until the close of the Company’s Annual General Meeting of Shareholders in 2029, and until their respective successors are duly elected and qualified, or until their respective offices are vacated in accordance with our Amended and Restated Articles of Association or the Companies Law 5759-1999 (the “Companies Law”);
	(2)	To re-approve the Company’s Compensation Policy for Executive Officers and Directors;
	(3)	To approve the re-appointment of Uzi Sofer, our Chief Executive Officer, to continue serving as Chairman of the board of directors of the Company (the “Board”);
	(4)	To approve a compensation package for Uzi Sofer, our Chief Executive Officer and Chairman;
	(5)	To approve the extension of terms of certain options for directors and officers of the Company; and
	(6)	To approve the re-appointment of Kost Forer Gabbay & Kasierer, registered public accounting firm, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2026, and until the Company’s next annual general meeting of shareholders, and to authorize the Board (with power of delegation to its audit committee) to set the fees to be paid to such auditors.

All proposals were approved at the Meeting by the respective requisite majorities in accordance with the Companies Law, and the Company’s Amended and Restated Articles of Association, as described in the Proxy Statement which was attached as Exhibit 99.1 to the Company’s Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission on May 18, 2026.

This Form 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File Nos. 333-274457, 333-288240 and 333-295359) and Form S-8 (File Nos. 333-264169, 333-270406, 333-277733, 333-285745 and 333-294151).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Alpha Tau Medical Ltd.
Date: June 25, 2026	By:	/s/ Uzi Sofer
		Uzi Sofer
		Chief Executive Officer

2

FAQ

What did Alpha Tau Medical Ltd. (DRTS) announce in its June 2026 Form 6-K?

Alpha Tau Medical Ltd. reported the voting results of its June 23, 2026 Annual General Meeting. Shareholders approved all proposals, including director re-elections, compensation matters, option extensions, and re-appointment of the independent auditor for the 2026 fiscal year.

Which directors were re-elected at Alpha Tau Medical’s 2026 Annual General Meeting?

Shareholders re-elected David Milch and Ruth Alon as Class II directors. They will serve until the close of the company’s Annual General Meeting of Shareholders in 2029, or until successors are elected and qualified under the company’s governing documents and Israeli Companies Law.

How did Alpha Tau Medical (DRTS) shareholders vote on executive and director compensation?

Shareholders re-approved the Compensation Policy for Executive Officers and Directors and approved a compensation package for CEO and Chairman Uzi Sofer. These approvals confirm the company’s previously disclosed compensation framework described in its proxy materials for the June 23, 2026 meeting.

Did Alpha Tau Medical’s 2026 AGM approve the CEO also serving as Chairman?

Yes. Shareholders approved the continued service of Uzi Sofer, the Chief Executive Officer, as Chairman of the Board. This decision maintains the combined CEO-Chairman structure that the company presented and explained in the proxy statement circulated ahead of the meeting.

What auditor did Alpha Tau Medical Ltd. appoint for the year ending December 31, 2026?

Shareholders approved the re-appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm for the year ending December 31, 2026, and authorized the board or its audit committee to set the firm’s fees.

Were all proposals at Alpha Tau Medical’s June 23, 2026 AGM approved?

All proposals on the agenda were approved by the requisite majorities. These included director re-elections, compensation policy approval, CEO-Chairman role and compensation, option term extensions, and auditor re-appointment, consistent with the recommendations described in the company’s previously filed proxy statement.